FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Vukovic Vojo (Last) (First) (Middle) C/O SYNTA PHARMACEUTICALS CORP. 45 HARTWELL AVENUE (Street) LEXINGTON MA 02421 (City) (State) (Zip)					SYN SNTA 3. Dat 03/00	2. Issuer Name and Ticker or Trading Symbol SYNTA PHARMACEUTICALS CORP [SNTA] 3. Date of Earliest Transaction (Month/Day/Year) 03/06/2012 4. If Amendment, Date of Original Filed (Month/Day/Year)								Neck all app Direct X Office below SV Individual of the	SVP, Chief Medical Officer dividual or Joint/Group Filing (Check Applicable)			
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)					ction	on 2A. Deemed Execution Date,			3. Transaction Code (Ins	on	4. Securities Acquire Disposed Of (D) (Instant) and 5)		uired (A) o	5. Amount of Securities Beneficially Owned Following Reported		Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	(e.g., pt Title of Conversion or Exercise str. 3) Title of Conversion Date (Month/Day/Year) Or Exercise Price of Derivative Security (Month/Day/Year) (e.g., pt Execution Date, if any (Month/Day/Year)			uts, ca 4. Transact	Transaction of Code (Instr. B) Derivative (Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)									Owned 8. Price 9. Number derivative Derivative Securities Beneficiall		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
Employee Stock Option (Right to Buy)	\$4.22	03/06/2012			A		70,380	. /	(1)		06/2022	Common Stock	70,380	\$0	70,380		D	

Explanation of Responses:

1. The option vests as to 25% of the shares on March 6, 2013 and as to an additional 6.25% of the shares on the last day of each successive three-month period thereafter.

/s/ Ann Margaret Eames, Attorney-in-Fact 03/08/2012

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.